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Background: The dipeptidyl peptidase-4 (DPP-4) inhibitors Sitagliptin and Vildagliptin lower blood glucose by
augmenting endogenous levels of glucagon-like peptide-1 (GLP-1), an incretin which also confers cardioprotection.
As such, we hypothesized that treatment with DPP-4 inhibitors are also cardioprotective.
Methods: In ex vivo experiments: Male Sprague–Dawley rats were randomized to receive by oral gavage either
Vildagliptin (20 mg/kg/day), Sitagliptin (100 mg/kg/day), or water for 2 weeks. Excised hearts were Langendorff-
perfused with buffer containing either 5 mmol/L or 11 mmol/L glucose and subjected to 35 minutes ischaemia/
120 minutes reperfusion. In in vivo experiments: Male young Wistar and Sprague–Dawley rats, middle aged Wistar
and Goto-Kakizaki diabetic rats were randomized to receive by oral gavage either Sitagliptin (100 mg/kg/day), or
water for 2 weeks. Rats were then subjected to 30 minutes ischaemia/120 minutes reperfusion and infarct size
ascertained.
Results: Two weeks pre-treatment with either Vildagliptin or Sitagliptin reduced ex vivo myocardial infarction (MI)
size in hearts perfused with buffer containing 11 mmol/L glucose but not 5 mmol/L glucose. This effect was
abolished by Exendin 9–39 (GLP-1 receptor antagonist) and H-89 (PKA antagonist). Treatment of perfused hearts
with native GLP-1 was also glucose-sensitive, reducing MI size, at glucose concentrations 7, 9, and 11 mmol/L but
not at 5 mmol/L. Finally, Sitagliptin reduced in vivo MI size in middle aged Wistar (7-8 mmol/L glucose) and Goto-
Kakizaki (9-10 mmol/L glucose) rats where blood glucose was elevated, but not in young Wistar (5 mmol/L glucose)
or Sprague–Dawley (5 mmol/L glucose) rats, where blood glucose was normal.
Conclusions: We find that chronic treatment with DPP-4 inhibitors reduced MI size, via the GLP-1 receptor-PKA
pathway, in a glucose-dependent manner. Glucose-sensitive cardioprotection of endogenous GLP-1 in diabetic
patients may in part explain why intensive control of serum glucose levels has been associated with increased
cardiovascular risk.
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Coronary heart disease (CHD) is the leading cause of
death in diabetic patients. According to the World Health
Organisation more than 220 million people worldwide
have diabetes. Patients with diabetes are two to three
times more likely to develop CHD, and experience worse
clinical outcomes following an acute myocardial infarction
[1-3], coronary angioplasty [4], and cardiac bypass surgery
[5-7]. The reason for the worse cardiovascular outcomes
in diabetic patients is currently unclear. Pre-clinical ani-
mal studies suggest that there may be specific defects in
diabetic cardiomyocytes which may be responsible includ-
ing increased mitochondrial generation of reactive oxygen
species, impaired signalling via the PI3-Akt survival kinase
pathway and reduced rates of ATP synthesis (reviewed in
[8,9]). Clearly, novel cardioprotective strategies are re-
quired to improve clinical outcomes in diabetic patients
with CHD.
In this respect, emerging evidence suggests that the
incretin, glucagon-like peptide (GLP-1), GLP-1(7–36)
amide and its breakdown product GLP-1(9–36)amide
both have the ability to protect the heart against acute
ischaemia-reperfusion injury (IRI) [10-12], as well as
having direct beneficial effects on metabolism [13,14].
However, GLP-1 is rapidly broken down in the circula-
tion by the enzyme, dipeptidyl peptidase-4 (DPP-4). The
anti-diabetic agents, Sitagliptin and Vildagliptin both
lower blood glucose by inhibiting DPP-4, which aug-
ments endogenous levels of GLP-1 [15]. Therefore, in
this study we utilized both ex vivo and in vivo models of
ischaemia reperfusion injury (IRI) to investigate whether
chronic treatment with the DPP-4 inhibitors, Sitagliptin
and Vildagliptin, also confer cardioprotection.
Methods
Animals
Animal experiments were conducted in strict accordance
with the Animals (Scientific Procedures) Act 1986 pub-
lished by the UK Home Office and the Guide for the
Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No.
85–23, revised 1996). Approval has been granted by the
University College London ethics review board. All ef-
forts were made to minimize suffering.
Male Sprague–Dawley (SD) rats (3-4 months) were
used for the ex vivo isolated heart investigations. Male
SD rats (3–4 months), Wistar rats (3–4 months), middle
aged Wistar rats (7–8 months) and middle aged Goto
Kakizaki (GK) rats (7–8 months) were used for the
in vivo experiments. Animals received humane care in
accordance with the United Kingdom Animal (Scientific
Procedures) Act of 1986. Approval was granted by a uni-
versity ethics review board. The study conforms with the
Guide for the Care and Use of Laboratory Animalspublished by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996). For oral gavage,
Sitagliptin (100 mg/kg/day) and Vildagliptin (20 mg/kg/
day) were dissolved in water, concentrations sufficient to
increase GLP-1 levels [16,17]. All other reagents were of
standard analytical grade.
Ex vivo isolated perfused rat heart model of acute
myocardial infarction
Rats were terminally anesthetised with sodium pentobar-
bital (55 mg/kg intraperitoneally) and heparin (300 IU).
The hearts were rapidly excised into ice-cold buffer, and
mounted on a constant pressure (80 mmHg) Langendorff-
perfusion apparatus and perfused with modified Krebs-
Henseleit bicarbonate buffer in mmol/L: NaCl 118.5,
NaHCO3 25.0, KCl 4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2
1.7 and glucose 5.0 or 11.0. The buffer was gassed with
95%O2/ 5%CO2 and pH maintained at 7.35-7.45 at 37.0°C.
A suture was placed around the left main coronary ar-
tery and the ends inserted into a pipette tip to form a
snare. A latex, fluid-filled balloon was placed in the left
ventricle through an incision in the left atrial append-
age and inflated to a pressure of 8–10 mmHg. Left ven-
tricular developed pressure, heart rate and coronary
flow were monitored at regular intervals. Temperature
was constantly measured via a thermo-probe inserted
into the pulmonary artery and maintained between
37.0 ± 0.2°C. Regional myocardial ischaemia was in-
duced by tightening the suture placed around the left
anterior descending coronary artery (LAD) for 35 mi-
nutes and reperfusion for 120 minutes initiated by re-
leasing the snare. At the end of the reperfusion period
the suture was tied and the heart perfused with 0.25%
Evans Blue in saline to delineate the area at risk. Hearts
were frozen at −20°C for several hours before infarct
size determination.
In vivo rat model of acute myocardial infarction
Rats were anesthetised with sodium pentobarbital
(20 mg/kg intraperitoneally) and heparin (300 IU). The
rats were intubated and ventilated with a Harvard venti-
lator (room air, 70 strokes/min, tidal volume: 8-9 ml/kg).
Body temperature was maintained at 37.4 ± 1°C by
means of a rectal probe thermometer attached to a
temperature control system (CMA450). A lateral thora-
cotomy was performed to expose the heart and a suture
placed around the LAD. The suture was tightened using
a loop system to create LAD ligation and regional is-
chaemia which was confirmed by a change in ECG pro-
file. Following 30 minutes of ischaemia, the vessel was
reperfused for 120 minutes. At the end of reperfusion,
the heart was removed from the chest, the LAD per-
manently occluded and the heart perfused with 0.5%
Evans blue in saline to delineate the area at risk. Hearts
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Myocardial Infarct size determination
All hearts were sliced into 2 mm thick transverse sec-
tions and incubated in triphenyltetrazolium chloride so-
lution (TTC; 1% in phosphate buffer). TTC reacts with
intracellular dehydrogenases to stain viable risk zone tis-
sue red leaving the infarcted areas off-white. The slices
were then transferred and fixed in 10% formalin over-
night. All the slices from one heart were scanned into
the computer for analysis or drawn onto acetate, and the
area at risk, area of infarction, and area of viable risk
zone was delineated and converted to a volume assum-
ing a 2 mm slice thickness. Image J or computerised plan-
imetry (Summa Sketch III, Summagraphics, Seymour, CT,
USA) were then used to assess the percentage of infarcted
tissue in the myocardium area at risk (I/R%) [18].
Blood glucose assessment
Samples for fasting blood glucose were taken at baseline
and after 2 weeks treatment with Sitagliptin, Vildagliptin
or water control. Blood glucose measurements (mmol/L)
were determined using an ABL 700 series blood gas
analyzer (Radiometer, Copenhagen).
Experimental protocols for isolated heart perfusion
To investigate the effect of different glucose concentra-
tions within the perfusion buffer, isolated rat hearts were
perfused with 5 mmol/L versus 11 mmol/L glucose during
control and ischaemic preconditioned (IPC) experiments
(the latter used as a positive control). Hearts were per-
fused with buffer containing glucose at either 5 mmol/L
or 11 mmol/L and subjected to stabilization, ischaemia
and reperfusion or to a standard IPC protocol (2 cycles of
5 minutes global ischaemia and 10 minutes reperfusion)
prior to ischaemia and reperfusion.
Animals were randomly assigned to receive, Sitagliptin
(100 mg/kg/day), Vildagliptin (20 mg/kg/day) or water
alone given daily by oral gavage for 2 weeks. Hearts
were then excised from animals and mounted on the
Langendorff-apparatus, and randomized to receive one
of the experimental protocols summarized in Figures 1A
and 1B. To examine the role of GLP-1 and PKA in the
setting of the anti-diabetic gliptin drugs, Exendin 9–39
or DMSO (3 nM, a GLP-1 receptor antagonist, Sigma)
were added into the perfusate in selected experiments
and H-89 or DMSO (5 μM, a PKA antagonist, Sigma)
was administered by intraperitoneal (I.P) injection prior
to excision of the heart.
To investigate the cardioprotective effects of GLP-1
(0.3 nM, Novo Nordisk, Denmark) at different concen-
trations of glucose; hearts were rapidly excised from un-
treated rats and mounted on the Langendorff-apparatus.The perfusion buffer contained 5, 7, 9 or 11 mmol/L of
glucose; and either DMSO vehicle (0.01%) or GLP-1
(0.3 nM) throughout the entire protocol.
Experimental protocols for in vivo investigations
To investigate whether the cardioprotective effect of
DPP-4 inhibition were glucose sensitive in the in vivo
setting; rats with differing blood glucose levels were
treated by oral gavage with either Sitagliptin (100 mg/
kg/day) or water for 2 weeks prior to LAD occlusion/re-
perfusion. Four groups were assessed SD, Wistar, middle
aged Wistar and middle aged GK rats.
Statistical analysis
All values are expressed as mean ± SEM. Myocardial in-
farct size was analyzed by one-way ANOVA and Fisher’s
protected least significant difference test for multiple com-
parisons. Differences were considered significant when
P < 0.05.
Results
Both Sitagliptin and Vildagliptin pre-treatment reduced
myocardial infarct size ex vivo in a glucose-dependent
manner
There was no difference in the area at risk or haemo-
dynamic variables between the treatment groups. The
blood glucose levels after 2 week of treatment averaged
5.5 ± 0.3 mmol/L, 5.7 ± 0.2 mmol/L and 5.7 ± 0.4 mmol/L
for Sitagliptin, Vildagliptin and control, respectively.
Sitagliptin pre-treatment was found to reduce myocar-
dial infarct size in hearts perfused with buffer containing
11 mmol/L of glucose (30.7 ± 3.4% with Sitagliptin ver-
sus 57.9 ± 5.0% with control: P < 0.05:N ≥ 6/group) but
not 5 mmol/L glucose (51.4 ± 7.6% with Sitagliptin versus
53.1 ± 5.4% with control: P > 0.05:N ≥ 6/group) (Figure 2A).
Similarly, Vildagliptin pre-treatment reduced myocardial
infarct size in hearts perfused with buffer containing
11 mmol/L of glucose (34.4 ± 4.1% with Vildagliptin
versus 52.9 ± 5.2% with control: P < 0.05:N ≥ 6/group)
but not 5 mmol/L glucose (53.2 ± 4.8% with Vildagliptin
versus 52.6 ± 7.2% with control: P > 0.05:N ≥ 6/group)
(Figure 2B). Interestingly, ischaemic preconditioning
(IPC) (used as a positive control in this setting) reduced
myocardial infarct size in perfused rat hearts at both
5 mmol/L glucose (18.8 ± 2.7% with IPC versus 38.8 ±
4.3% with control: P < 0.05: N > 6/group) and 11 mmol/L
glucose (21.7 ± 4.8% with IPC versus 41.6 ± 3.9% with con-
trol: P < 0.05: N ≥ 6/group) (Figure 2C).
Pharmacological inhibition of the GLP-1 receptor and the
PKA signalling pathway abrogated both Sitagliptin and
Vildagliptin-induced cardioprotection
There was no difference in the area at risk or haemo-
dynamic variables between the treatment groups. The
Sitagliptin 100mg/kg/day
Sprague Dawley rats treated for 2 weeks
Water
Infarct assessment with TTC.
I/R at 11mmol/L alone or  
added 0.01% DMSO or 
added 3nM Exendin-9-39
I/R at 5mmol/LI/R at 5mmol/L
I/R at 11mmol/L alone or
added 0.01% DMSO or 
added 3nM Exendin-9-39
A
Excision of heart for 
Langendorff perfusion
Excision of heart for 
Langendorff perfusion
Vildagliptin 20mg/kg/day
Sprague Dawley rats treated for 2 weeks
Water
Infarct assessment with TTC.
I/R at 11mmol/L alone or  
added 0.01% DMSO or 
added 3nM Exendin-9-39
I/R at 5mmol/LI/R at 5mmol/L
I/R at 11mmol/L alone or  
added 0.01% DMSO or 
added 3nM Exendin-9-39
Excision of heart for 
Langendorff perfusion
Excision of heart for 
Langendorff perfusion
I.P injection of H-89 or 
DMSO
I.P injection of H-89 or 
DMSO
B
Figure 1 Ex-vivo experimental schedule for Sitagliptin and Vildagliptin pre-treatment. (A) Sprague–Dawley rats were treated for 2 weeks
Sitagliptin (100 mg/kg/day) or water. (B) Sprague–Dawley rats were treated for 2 weeks Vildagliptin (20 mg/kg/day) or water. All hearts were
subjected to 35 minutes ischaemia followed by 120 minutes reperfusion (I/R).
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cose were abolished by Exendin 9–39 (a GLP-1 recep-
tor antagonist) (63.6 ± 5.5% with Sitagliptin + Exendin
9–39 versus 61.4 ± 3.0% with Control + Exendin 9–39:
P > 0.05:N > 7/group)(Figure 2A) and the cardioprotec-
tive effects of Vildagliptin were abolished in the pres-
ence of Exendin 9–39 and H-89 (a PKA inhibitor) (61.5 ±
3.3% with Vildagliptin + Exendin 9–39 and 59.4 ± 2.1%
with Vildagliptin +H-89 versus 35.0 ± 5.0% with Vildaglip-
tin + vehicle: P < 0.05:N ≥ 6/group)(Figure 3). Import-
antly, the pharmacological inhibitors themselves didnot influence infarct size significantly (61.4 ± 3.0% with
control + Exendin 9–39 and 53.0 ± 4.9% with control +
H-89 versus 53.1 ± 3.1% with control + vehicle: P > 0.05:
N ≥ 6/group) (Figure 3).
The infarct-limiting effects of GLP-1 treatment are also
glucose-sensitive
There was no difference in the area at risk or haemo-
dynamic variables between the treatment groups. The per-
fusion of hearts with buffer containing GLP-1 reduced MI
size, at glucose concentrations 7, 9, and 11 mmol/L but
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Figure 2 Ex-vivo myocardial infarct size following Sitagliptin or
Vildagliptin pre-treatment. (A) Ex vivo myocardial infarct size
expressed as a percentage of the risk zone. A. Pre-treatment with
Sitagliptin (Sita) reduced the myocardial infarct to area at risk ratio
(I/R%) in isolated rat hearts perfused with buffer containing 11 but
not 5 mmol/L glucose. This infarct-limiting effect was abolished in
hearts Langendorff-perfused with Exendin 9–39 (Exendin), a GLP-1
receptor antagonist. *P < 0.05. N≥ 6/group. (B) Pre-treatment with
Vildagliptin (Vilda) reduced the myocardial infarct to area at risk ratio
(I/R%) in isolated rat hearts perfused with buffer containing 11 but
not 5 mmol/L glucose. *P < 0.05. N≥ 6/group. (C) Ischaemic
preconditioning (IPC) reduces the myocardial infarct to area at risk
ratio (I/R%) in isolated rat hearts perfused with buffer containing
either 5 or 11 mmol/L glucose. *P < 0.05. N ≥ 6/group.
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9 mmol/L, 39.1 ± 2.5% at 11 mmol/Lpretreatment did not
reduce blood glucose levels in any of the groups. versus
55.6 ± 1.2% at 5 mmol/L:P < 0.05:N ≥ 6/group) (Figure 4A).
There was no difference in MI size in control hearts per-
fused at the different glucose concentrations (57.1 ± 0.7%
at 5 mmol/L, 52.7 ± 1.2% at 7 mmol/L, 55.6 ± 1.5% at
9 mmol/L, 50.1 ± 2.9% at 11 mmol/L:P > 0.05:N ≥ 6/group)
(Figure 4B).Sitagliptin pre-treatment reduced myocardial infarct size
in vivo in a glucose-dependent manner
Blood glucose levels were not significantly different be-
tween SD and Wistar rats, but were significantly different
between these groups and middle aged Wistar and GK rats
(in mmol/L: 5.5 ± 0.3, 5.6 ± 0.2, 7.5 ± 0.3 and 9.3 ± 1.5, re-
spectively. P < 0.05:N ≥ 6/group). Sitagliptin pre-treatment
did not reduce blood glucose levels in any of the groups.
In the in vivo LAD occlusion/reperfusion studies,
Sitagliptin pre-treatment was found to reduce myocar-
dial infarct size in both middle aged Wistar and GK
rats (15.4 ± 2.4% with Sitagliptin versus 44.8 ± 4.0% with
control in Wistars; and 29.10 ± 5.3% with Sitagliptin
versus 60.9 ± 5.5% with control in GKs. P < 0.05:N ≥ 6/
group). However, in the SD or Wistar groups there
were no differences in MI size (42.1 ± 7.4% and 34.5 ±
5.9% with Sitagliptin versus 46.6 ± 5.7% and 33.8 ± 3.1%
with control, respectively for SD and Wistar) (Figure 5
A,B).0
10
20
30
40
50
60
70
*
In
fa
rc
t t
o 
ar
ea
 a
t r
isk
 r
at
io
 (I
/R
%
)
Control+
vehicle
Vilda+
vehicle
Control+
Exendin
Vilda
+ H-89 
Control
+H-89
Vilda+
Exendin
11 mmol/L
glucose
Figure 3 Ex vivo myocardial infarct size expressed as a
percentage of the risk zone. The reduction in myocardial infarct to
area at risk ratio (I/R%) induced by pre-treatment with Vildagliptin
(Vilda) was abolished by treatment with either Exendin 9–39
(Exendin), a GLP-1 receptor antagonist, or H-89 (a PKA antagonist).
*P < 0.05. N≥ 6/group.
010
20
30
40
50
60
70
* **
In
fa
rc
t t
o 
ar
ea
 a
t r
isk
 r
at
io
 (I
/R
%
)
Control
11mmol/L
Control
5 mmol/L
Control
7 mmol/L
Control
9 mmol/L
Control
11 mmol/L
GLP-1
11 mmol/L
GLP-1
5 mmol/L
GLP-1
7 mmol/L
GLP-1
9 mmol/L
0
10
20
30
40
50
60
70
In
fa
rc
t t
o 
ar
ea
 a
t r
isk
 r
at
io
 (I
/R
%
)
A
B
Figure 4 Ex-vivo myocardial infarct size expressed as a
percentage of the risk zone. (A) There was no difference in
myocardial infarct to area at risk ratio (I/R%) in hearts perfused with
buffer containing glucose at either 5, 7, 9, or 11 mmol/L. *P < 0.05.
N≥ 6/group. (B) Perfusion of isolated rat hearts with buffer
containing GLP-1 reduced myocardial infarct to area at risk ratio
(I/R%) in hearts perfused with buffer containing glucose at 7, 9, or
11 mmol/L but not at 5 mmol/L. *P < 0.05. N ≥ 6/group.
0
10
20
30
40
50
60
70
*
*
In
fa
rc
t t
o 
ar
ea
 a
t r
isk
 r
at
io
 (I
/R
%
)
Control ControlControlSita SitaSita
Wistar
Middle aged 
Wistar
Middle aged 
GKSD
Control Sita
5.5±0.3mmol/L 5.6±0.2mmol/L 7.5±0.3mmol/L 9.3±1.5mmol/L
A
B
Figure 5 Effect of Sitagliptin pre-treatment on in vivo myocardial
infarct size. (A) Myocardial infarct size is expressed as a percentage of
the risk zone. Sitagliptin pre-treatment reduced myocardial infarct to
area at risk ratio (I/R%) in middle aged Wistar and GK rats. There was
no difference in myocardial infarct to area at risk ratio in SD or Wistar
rats. * P < 0.05:N≥ 6/group. (B) Representative short axis slices of
control and treated hearts depicting non-ischemic zone (blue), area of
myocardial infarction (white), and non-infarcted viable myocardium in
the area at risk (red).
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The main findings from the present study are as follows:
(a) We report that chronic oral treatment with the DPP-4
inhibitors, Sitagliptin or Vildagliptin, is cardioprotective as
evidenced by a significant reduction in myocardial infarct
size in the isolated perfused rat heart; (b) Interestingly, we
show that for the first time, the infarct-limiting effects of
Sitagliptin and Vildagliptin pre-treatment are sensitive to
the glucose levels present during the myocardial infarc-
tion, such that cardioprotection was only observed in
hearts infarcted in the presence of a high glucose of
11 mmol/L, with loss of cardioprotection at lower glucose
levels of 5 mmol/L; (c) The infarct-limiting effects of DPP-
4 inhibitors were abrogated by pharmacological inhibitors
of the GLP-1 receptor and the PKA signalling pathway;
(d) The cardioprotection elicited by GLP-1 treatment wasalso glucose-sensitive with infarct limitation observed at
glucose levels of 7, 9 and 11 mmol/L but not at 5 mmol/L;
(e) Sitagliptin related cardioprotection is also dependent
on circulating glucose levels in the in vivo setting.
GLP-1 cardioprotection
Previous experimental studies have demonstrated that ex-
ogenous GLP-1 is cardioprotective. These cardioprotective
effects were attributed to GLP-1 receptor activation and
subsequent recruitment of numerous intracellular signal-
ling pathways involving Akt, Erk1/2, p70S6K, and AMPK
as well as the downstream phosphorylation and inhibition
of the pro-apoptotic protein BAD (reviewed in [10]). In
the current study we were keen to investigate whether en-
dogenous GLP-1 levels, which are augmented by DPP-4
inhibitor therapy, also confer cardioprotection. Whilst
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reported infarct-limitation with chronic Sitagliptin therapy
through the activation of PKA. Interestingly, in that
particular study the average blood glucose was about
7.5 mmol/L, which corresponds to the levels of glucose in
which we observed cardioprotection in our study. GLP-1
has also been suggested to improve myocardial contractil-
ity. GLP-1 enhanced cardiac voltage-gated L-type Ca2+
currents I(Ca) in canine ventricular cardiomyocytes. Inter-
estingly, this augmentation was linked to the activation of
cAMP-dependent PKA [20].
In contrast, Sauve and co-workers [21] failed to dem-
onstrate myocardial infarct limitation with either genetic
or pharmacological inhibition of DPP-4 using DPP-4
knockout mice and Sitagliptin, respectively, even though
the blood glucose level was at 10 mmol/L. Finally, it was
also demonstrated that pre-treatment with Vildagliptin
did not reduce MI size or prevent adverse LV remodel-
ling in rats subjected to MI [22]. However, it is worth
noting that in all these studies, these results were
obained following permanent LAD ligation, and not a
reperfusion MI model and in fact in two of these studies,
DPP-4 inhibition exhibited improved survival rates.
Interestingly, Zhao et al. [23] also demonstrated that ex-
ogenous GLP-1 was able to improve the recovery of left
ventricular function in isolated Langendorff-perfused rat
hearts subjected to acute IRI at 5 mM glucose. However,
in contrast to our study, the low-flow global myocardial
ischaemia model was used making a direct comparison
of results difficult.
Other effects of DPP-4 inhibition
Of note, an earlier experimental study attributed the car-
dioprotective effects of DPP-4 inhibition to the augmenta-
tion of endogenous stromal derived factor-1 (SDF-1), a
known chemokine substrate of DPP-4 [24]. This latter
study illustrates the non-specificity of DPP-4 inhibition for
GLP-1, as it has a number of substrates including other
gastrointestinal hormones, neuropeptides, cytokines, and
chemokines [25]. In this regard, it was important for us to
demonstrate that the DPP-4 inhibitor induced infarct-
limitation in the isolated heart was blocked by GLP-1 re-
ceptor and PKA antagonists, suggesting the involvement
of the myocardial GLP-1 receptor and subsequent acti-
vation of PKA. Furthermore, the observed glucose- sen-
sitivity was also reproduced in vivo in animal models
and with GLP-1, providing confirmatory evidence of
the mediatory role of endogenous GLP-1 in DPP-4 in-
hibitor cardioprotection.
Glucose-dependent cardioprotection
Of interest, our study is the first to report infarct limita-
tion with chronic Sitagliptin and Vildagliptin therapy be-
ing glucose-dependent, such that infarct-limitation wasobserved at a glucose level of 11 mmol/L and not at
5 mmol/L. Interestingly, the glucose-dependency was
also observed in GLP-1 mediated cardioprotection with
infarct-limitation being observed at glucose levels of 7,
9, and 11 mmol/L but not at 5 mmol/L. Moreover, the
finding that Sitagliptin pre-treatment in middle aged
Wistar and GK diabetic rats, both with hyperglycaemic
blood glucose levels, limited infarct size but these effects
were lost in normoglycaemic SD and Wistar rats,
strengthens the idea that glucose-dependent cardiopro-
tection with these agents is in fact an interesting
phenomenon. It was important for us to demonstrate
that the positive control for cardioprotection, ischaemic
preconditioning, was still effective in hearts perfused
with either 5 or 11 mmol/L, demonstrating that infarct-
limitation was possible at the lower blood glucose level
in our model. The reason for the glucose-dependency of
the cardioprotection elicited by both DPP-4 inhibitors
and GLP-1 is not known and further studies are clearly
required to investigate the mechanism underlying this
observation.
Interestingly, it has been suggested that GLP-1 does not
lower blood glucose at levels lower than 5 mM and there-
fore the risk of hypoglycemia is significantly reduced.
Previous experimental studies have reported glucose-
dependent changes in intracellular calcium and GLP-1
receptor-PKA signalling favouring high blood glucose
levels [26]. Alternatively, the GLP-1 receptor could be dif-
ferentially regulated in response to circulating blood glu-
cose levels. In the presence of high glucose, GLP-1 could
possibly activate G-protein coupled receptor signalling via
its Gi signalling pathway involving the Akt component of
the RISK pathway leading to cardioprotection [27,28],
whereas in conditions of low blood glucose this cardiopro-
tective pathway is not favoured. Chai et al. [29] have re-
cently showed that the administration of GLP-1 increased
Akt-phosphorylation in cultured cells. However, the link
between GLP-1, high glucose and Akt phosphorylation is
yet to be fully investigated. Recent evidence has implicated
AMPK as a mediator of GLP-1 cardioprotection [30], and
low glucose levels have been shown to activate AMPK
[31,32], and so the modulation of AMPK may explain in
part the glucose-sensitivity of GLP-1 cardioprotection.
Study limitations
There are several limitations to the current experimental
study: (1) Because we only reperfused the hearts for 2 hours
in our in vivo model of acute IRI, we do not know if the
cardioprotective effect elicited by the DPP-4 inhibitors had
a long-term infarct-limiting effect: (2) The findings pre-
sented here concerning the glucose-sensitivity of GLP-1
cardioprotection are purely descriptive. Clearly further
studies are required to elucidate the potential mechanisms
underlying the glucose-sensitivity; (3) We only investigated
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induced cardioprotection and ideally we should have also
shown that H-89 blocked Sitagliptin mediated cardiopro-
tection; (4) We did not measure serum levels of GLP-1.Clinical implications
Although, proof-of-concept clinical studies have demon-
strated cardioprotective benefit with exogenous GLP-1
therapy in the clinical settings of acute myocardial in-
farction [33], coronary artery bypass graft surgery [34]
and heart failure [35], this treatment regimen requires a
chronic subcutaneous infusion of GLP-1 given that the
GLP-1 is rapidly broken down in the body by the en-
zyme DPP-4. Therefore, the findings of the current study
suggest that augmenting endogenous levels of GLP-1
using clinically available DPP-4 inhibitors such as Sita-
gliptin and Vildagliptin may provide for a therapeutic
strategy, which not only treats the diabetes but also pro-
tects the heart from ischaemia-reperfusion injury, the
major cardiac complication of diabetes. An alternative
strategy to DPP-4 inhibition would be to administer clin-
ically available GLP-1 analogues such as Liraglutide [36]
and Exenatide [37,38] which are resistant to DPP-4 and
are also cardioprotective in animal studies. Clinical
studies are already underway investigating both GLP-1
analogues (Pharmacological Postconditioning to Reduce
Infarct Size Following Primary PCI [POSTCON II]:
ClinicalTrials.gov Identifier NCT00835848 and Effect
of Additional Treatment With EXenatide in Patients
With an Acute Myocardial Infarction (the EXAMI
Trial: ClinicalTrials.gov Identifier NCT01254123) and
DPP-4 inhibitors [39,40] as therapy for cardiovascular
disease. Lonborg et al. [41] has shown that the GLP-1
analogue, Exenatide, could reduce MI size when admin-
istered prior to PPCI in non-diabetic STEMI patients
when compared to control. In that particular study the
blood glucose ranged from 5–8 mmol/L. It would be
interesting to know whether the cardioprotective effect
of Exenatide was affected by the presenting blood glu-
cose levels.Conclusions
Our present study confirms that DPP-4 inhibitors elicit
cardioprotection against acute IRI similar to that seen
for GLP-1, moreover these effects appear to be glucose-
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